<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568464</url>
  </required_header>
  <id_info>
    <org_study_id>VCD/IE-ESFT</org_study_id>
    <nct_id>NCT00568464</nct_id>
  </id_info>
  <brief_title>Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)</brief_title>
  <official_title>Phase II Study of VCD/IE in the Treatment of the Patients With Ewing's Sarcoma Family of Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial was to evaluate the efficacy and tolerability of the
      sequential therapy of VCD/IE in the patients with ESFT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      80-90% patients of ESFT will develope disease progression during the period of local
      treatment (surgery or radiation). The survival has been improved in these 30 years due to
      chemotherapy. VCD/IE is widely used in the world for the patients with ESFT, but it is rarely
      used in China due to its high dosage.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The enrollment is slower than expected
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>every two cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>every cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Ewing's Sarcoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VCR, CTX, ADM; IFO, VP-16</intervention_name>
    <description>VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>VCD/IE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range 10-65 years old

          -  Histological confirmed ESFT

          -  No previous therapy

          -  ECOG performance status less than 2

          -  Life expectancy of more than 12 weeks

          -  Normal laboratory values: hemoglobin&gt;8.0g/dl, neutrophil&gt;2×109/L, platelet &gt; 80×109/L,
             Hb &gt; 80×1012/L, serum creatine &lt; 1×upper limitation of normal(ULN), serum bilirubin &lt;
             1.5×ULN, ALT and AST &lt; 2.5×ULN

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Received treatment for the disease previously

          -  Serious uncontrolled diseases and intercurrent infection

          -  The evidence of CNS metastasis and bone marrow involvement

          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             in-situ of uterine cervix

          -  History of allergy to the drugs in this trial

          -  Abnormal LVEF level
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ye Guo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>July 6, 2009</last_update_submitted>
  <last_update_submitted_qc>July 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Base for drug clinical trials, Fudan University cancer hospital</name_title>
    <organization>Fudan University cancer hospital</organization>
  </responsible_party>
  <keyword>ESFT (Ewing's sarcoma family of tumors)</keyword>
  <keyword>Response rate</keyword>
  <keyword>TTP</keyword>
  <keyword>OS</keyword>
  <keyword>Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

